Viewing nowCombinationSitaone Plus Tablet 50/500 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 202204586 · Approved 2022.12.21 · Insurance code 657807990
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to achieve better blood sugar control when combined with diet and exercise. Sitagliptin and metformin work together to help manage blood sugar levels in a stable manner. Therefore, it is used for improving blood sugar in patients with type 2 diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medication because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication contains sitagliptin and metformin, which are diabetes treatments that help control blood sugar. First, serious hypersensitivity reactions may occur while taking this medication; therefore, if symptoms such as skin rash, itching, or difficulty breathing appear, stop taking it immediately and consult a doctor. Additionally, this medication can cause acute pancreatitis, a serious inflammation of the pancreas, so symptoms like abdominal pain, nausea, vomiting, or fever should be reported to medical staff immediately. The metformin component can rarely cause lactic acidosis, a serious metabolic disturbance. If sudden fatigue, muscle pain, difficulty breathing, abdominal pain, or changes in consciousness occur, visit the hospital immediately. Patients with reduced kidney function, severe infections or dehydration, acute heart failure, or myocardial infarction should not take this medication. If undergoing tests using iodine contrast agents, this medication should be stopped for some time before and after the test. Pregnant women or women with a possibility of pregnancy, as well as nursing mothers, should not take this medication. This medication can cause hypoglycemia, so caution is needed, especially if meals are skipped or irregular, when engaging in intense exercise, or when taken with other blood sugar-lowering agents. Regular kidney function and blood tests are recommended, and vitamin B12 levels should be checked periodically. Alcohol consumption can increase the risk of side effects from this medication, so excessive drinking should be avoided during use. If surgery is planned or in cases of severe illness, temporarily discontinuing this medication may be necessary, and it can be resumed once the condition stabilizes. Lastly, if any unusual symptoms such as sudden joint pain or skin blisters occur while taking this medication, consult a doctor immediately.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture, and keep it at a temperature between 1 and 30 degrees Celsius. This storage will help maintain the medication's effectiveness and prevent deterioration.
Bright pink oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.